SCHEMBL35345

SCHEMBL35345

Cn1cc(Br)c(=O)[nH]c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.57
ALDH1A1 P00352 2/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
GAA P10253 1/20 0.44
DAO P14920 1/20 0.43
SQOR Q9Y6N5 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 2/20 0.41
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA4 P48058 1/20 0.41
GRIK5 Q16478 1/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CRBN Q96SW2 1/20 0.40
ASAH1 Q13510 1/20 0.40
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11144152 0.98 TDP1 (0.55) TDP1ALDH1A1CA1CA2GAA
SCHEMBL16248 0.74 MAPK1 (0.47) ALDH1A1DAOPOLBCRBNLMNA
SCHEMBL26044336 0.74 TDP1 (0.53) TDP1ALDH1A1CA1CA2GAA
SCHEMBL400005 0.73 TDP1 (1.00) TDP1ALDH1A1CA1CA2GAA
SCHEMBL4379234 0.73 LMNA (0.46) ALDH1A1DAOSQORCYP1A2KMT2A
SCHEMBL23224166 0.73 DAO (0.43) TDP1GAADAOKMT2APOLB
SCHEMBL2986044 0.73 DAO (0.46) TDP1GAADAOCYP1A2CYP2C19
SCHEMBL22114444 0.73 TDP1 (0.57) TDP1ALDH1A1CA1CA2GAA
SCHEMBL4379055 0.73 DAO (0.43) DAOCYP1A2KMT2AGRIA1GRIA2
SCHEMBL4379053 0.73 DAO (0.43) ALDH1A1DAOCYP1A2KMT2AGRIA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119662655-A Application of RNA molecule and composition thereof in tumor immunotherapy 武汉厚先生物医药有限公司 2025-03-21 CN disclosed
WO-2023183852-A9 PHOSPHONATE PRODRUGS AND USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2023-11-23 WO disclosed
CN-116916936-A Compositions and methods for delivering RNA 再生技术有限责任公司 2023-10-20 CN disclosed
US-20230309833-A1 METHODS AND MATERIALS FOR USING [18F]-F-ARAG IN CARDIAC IMAGING CELLSIGHT TECHNOLOGIES INC. (US) 2023-10-05 US disclosed
US-20230309833-A1 METHODS AND MATERIALS FOR USING [18F]-F-ARAG IN CARDIAC IMAGING CELLSIGHT TECHNOLOGIES INC. (US) 2023-10-05 US disclosed
WO-2023183852-A1 PHOSPHONATE PRODRUGS AND USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2023-09-28 WO disclosed
CN-115515559-A Rectal delivery of messenger RNA 翻译生物公司 2022-12-23 CN disclosed
EP-3797782-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS Janssen BioPharma, Inc. (US) 2021-03-31 EP disclosed
EP-2880033-B1 CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA LP (US) 2020-06-17 EP disclosed
WO-2019032612-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2019-02-14 WO disclosed
EP-2013344-A2 ANTISENSE AGENTS COMBINING STRONGLY BOUND BASE - MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE Baltic Technology Development, Ltd. (EE) 2009-01-14 EP disclosed
US-20080255358-A1 Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases GLAXO GROUP LIMITED (GB) 2008-10-16 US disclosed
EP-1861095-A1 DERIVATIVES OF IMIDAZO(1,2-A)PYRIDINE USEFUL AS MEDICAMENTS FOR TREATING GASTROINTESTINAL DISEASES GLAXO GROUP LIMITED (GB) 2007-12-05 EP disclosed
WO-2007125173-A2 ANTISENSE AGENTS COMBINING STRONGLY BOUND BASE - MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE BALTIC TECHNOLOGY DEVELOPMENT, LTD. (EE) 2007-11-08 WO disclosed
US-20070259830-A1 Antisense Agents Combining Strongly Bound Base-Modified Oligonucleotide and Artificial Nuclease BALTIC TECHNOLOGY DEVELOPMENT (EE) 2007-11-08 US disclosed
WO-2006100119-A1 DERIVATIVES OF IMIDAZO (1,2-A) PYRIDINE USEFUL AS MEDICAMENTS FOR TREATING GASTROINTESTINAL DISEASES GLAXO GROUP LIMITED (GB) 2006-09-28 WO disclosed
EP-0586523-A4 DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF UNIV YALE (US) 1995-11-29 EP disclosed
EP-0586523-A1 DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF YALE UNIVERSITY (US) 1994-03-16 EP disclosed
US-5213972-A Production of thymidine and deoxyuridine, intermediates for AZT CHEMGEN CORPORATION (US) 1993-05-25 US disclosed
WO-1992020816-A1 DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF YALE UNIVERSITY (US) 1992-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255358-A1 Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases ALPI, PYGL, PPIP5K2 TDP1 2987/4885ALDH1A1 627/4885CA1 3728/4885
US-20070259830-A1 Antisense Agents Combining Strongly Bound Base-Modified Oligonucleotide and Artificial Nuclease NCL, RNGTT, POLRMT TDP1 316/4885ALDH1A1 4074/4885CA1 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.